Janux Therapeutics - Postive trial data, Feb 27 2024:
Janux Therapeutics shares tripled after promising Phase 1 trial results for their immunotherapies against solid tumors, particularly in metastatic prostate cancer. Analysts, including Jonathan Miller, deemed the data "best-in-class," propelling the company's valuation to $2 billion, with shares surging over 200%.
Full Article: https://www.biopharmadive.com/news/janux-t-cell-engager-cancer-drug-data-shares/708621/
Frontier Medicines - Investment (Series C), Feb 23 2024
Frontier Medicines closed an $80 million funding round to advance its KRAS blocker, FMC-376. With a total capital of $235.5 million, the funding was led by Deerfield Management and Droia Ventures, with support from Galapagos NV and others. FMC-376, dosed in its first patient for the Phase I/II PROSPER trial, targets G12C-mutated KRAS cancers with a unique dual mechanism, showing promise in overcoming treatment resistance.
Full Article: https://www.biospace.com/article/frontier-raises-80m-in-series-c-targets-amgen-and-bms-in-kras-/?s=183
Precirix, CEO Change, Feb 29 2024
Tom Plitz, the newly appointed CEO of Precirix, brings a wealth of experience with a strong R&D background and entrepreneurial skills, having previously led Chord Therapeutics and served as CSO of Wilson Therapeutics. With a focus on precision radiopharmaceuticals, Precirix utilizes camelid single-domain antibodies as carrier molecules, showcasing expertise in theranostic approaches.
Full article: https://precirix.com/news-and-events/2024-02-29/tom-plitz-commences-role-as-chief-executive-officer-of-precirix
Gilead Sciences, Venture Funding Update, Feb 29 2024
A venture capital group linked with Carlyle, is set to invest up to $210 million to support Gilead Sciences in expanding the approved applications of the cancer drug Trodelvy. Initially approved in the U.S. in April 2020 for breast cancer treatment, Trodelvy came under Gilead's ownership through the acquisition of Immunomedics for $21 billion later that year.
Full Article: //www.biopharmadive.com/news/gilead-abingworth-trodelvy-deal-launch-therapeutics-lung-cancer/708897/
FogPharma, Series E Funding, Mar 1 2024
FogPharma has secured $145 million in a recent funding round, marking its Series E financing. The funds will significantly support the progress of FOG-001, the company's leading drug candidate focused on inhibiting tumor growth by targeting the beta-catenin protein. Currently undergoing a Phase 1/2 study, this drug holds promise in cancer treatment.
Full article: https://www.biopharmadive.com/news/fogpharma-series-e-venture-funding-cancer-peptides/709040/
Blossom, Series B Funding, Feb 29 2024
BlossomHill Therapeutics' Series B funding, has attracted $100 million from life sciences investors. The startup, led by decorated scientist Jean Cui, who played a pivotal role in inventing two targeted cancer drugs at Pfizer and led the development of the approved lung cancer treatment Augtyro at Turning Point Therapeutics, aims to build a robust drug pipeline with the newly acquired funds.
Full Article: ://www.biopharmadive.com/news/blossomhill-jean-cui-cancer-small-molecule-series-b/708901/
BioNtech, C-Suite Change, 7th March
𝗣𝗹𝗮𝗻𝗻𝗲𝗱 𝗥𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗖𝗖𝗢 & 𝗖𝗕𝗢 𝗦𝗲𝗮𝗻 𝗠𝗮𝗿𝗲𝘁𝘁+++
Full Release: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-planned-retirement-sean-marett
Convergent Therapeutics - Executive Changes, Mar 4 2024:
Convergent Therapeutics has appointed Scott Myers as Chairman of its Board of Directors. Myers, with a rich background as President and CEO of various biotech companies including Viridian and Rainier Therapeutics, brings extensive experience to Convergent's leadership team. His appointment underscores Convergent's commitment to utilizing seasoned expertise in advancing its innovative therapies.
Fibrogen - Executive Changes, March 8 2024:
FibroGen, Inc. today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024.
Full Article: https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-appoints-deyaa-adib-md-chief-medical-officer
